Another study of 195 postmenopausal females with stage I or II ERα-positive breast cancer who underwent endocrine therapy showed that ERβ overexpression results in reduced disease-free survival (DFS) and poor prognosis [49]. The gene discussed is ESR2; the disease is breast cancer.